[
    {
        "content": "* European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis",
        "date": "11132017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug "
    },
    {
        "content": "* Arbutus\u2019 LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran",
        "date": "11162017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Arbutus\u2019 LNP licensee Alnylam initiates rolling submission of NDA for Patisiran "
    },
    {
        "content": "* Alnylam Pharmaceuticals announces proposed public offering of $675 000 000 of common stock",
        "date": "11132017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam announces proposed public offering to raise about $675 mln "
    },
    {
        "content": "* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis",
        "date": "11162017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment "
    },
    {
        "content": "* Alnylam Pharmaceuticals reports third quarter 2017 financial results and highlights recent period activity",
        "date": "11072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06 "
    },
    {
        "content": "* Alnylam announces successful outcome following fda type a meeting to discuss fitusiran program in hemophilia",
        "date": "11092017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam announces successful outcome following FDA type A meeting "
    },
    {
        "content": "* Alnylam initiates ENVISION Phase 3 clinical study with givosiran  an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias (AHPs)",
        "date": "11072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam initiates ENVISION Phase 3 clinical study with givosiran "
    },
    {
        "content": "* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran",
        "date": "11062017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran "
    },
    {
        "content": "More than half of patients with a rare  rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology  according to results of a late stage study presented on Thursday.",
        "date": "11022017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "Alnylam RNAi drug reverses progress of rare fatal disease: study "
    },
    {
        "content": "Nov 2 More than half of patients with a rare  rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology  according to results of a late stage study presented on Thursday.",
        "date": "11022017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "REFILE-UPDATE 2-Alnylam RNAi drug reverses progress of rare fatal disease -study "
    },
    {
        "content": "Nov 2 More than half of patients with a rare  rapidly progressing fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology  according to results of a late stage study released on Thursday.",
        "date": "11022017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "Alnylam RNAi drug reverses progress of rare fatal disease - study "
    },
    {
        "content": "Drugmaker Alnylam Pharmaceuticals has lost its bid to dismiss counterclaims that rival Dicerna Pharmaceuticals asserted in response to a trade secrets lawsuit brought by Alnylam two years ago.",
        "date": "10242017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "Alnylam loses bid to toss Dicerna counterclaims in trade secrets case "
    },
    {
        "content": "Oct 18 Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.",
        "date": "10182017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "CORRECTED-UPDATE 1-Alnylam  Vir partner on RNAi-based hep B treatment "
    },
    {
        "content": "Oct 18 Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases  including chronic hepatitis B.",
        "date": "10182017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "CORRECTED-Alnylam  Vir partner on RNAi-based drugs for infectious diseases "
    },
    {
        "content": "Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.",
        "date": "10182017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "Alnyalm  Vir partner on RNAi-based hep B treatment "
    },
    {
        "content": "* Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases",
        "date": "10182017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases "
    },
    {
        "content": "* Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5) in patients with atypical hemolytic-uremic syndrome (aHUS)",
        "date": "09262017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5) "
    },
    {
        "content": "Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study  in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.",
        "date": "09202017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "Alnylam's RNAi drug succeeds in key study  shares soar "
    },
    {
        "content": "* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse",
        "date": "09202017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "UPDATE 4-Alnylam's RNAi drug succeeds in key study  shares soar "
    },
    {
        "content": "* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy",
        "date": "09202017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study "
    },
    {
        "content": "Sept 20 Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease.",
        "date": "09202017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "Alnylam's genetic disease drug meets main goal in key study "
    },
    {
        "content": "Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died  sending its shares sharply down.",
        "date": "09072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "Alnylam stock plummets after patient death in hemophilia study "
    },
    {
        "content": "* Alnylam says will resume trials as soon as possible (Adds details  analyst's comments)",
        "date": "09072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "UPDATE 2-Alnylam stock plummets after patient death in hemophilia study "
    },
    {
        "content": "* Sanofi-\u200das disclosed by Alnylam  fatal thrombotic event occurred in patient with hemophilia without inhibitors enrolled in Phase 2 OLE study of fitusiran\u200b Source text for Eikon: Further company coverage:",
        "date": "09072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Sanofi alliance partner Alnylam gives update on fitusiran "
    },
    {
        "content": "Sept 7 U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient's death.",
        "date": "09072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "Alnylam suspends bleeding disorder trial dosing after patient death "
    },
    {
        "content": "* Alnylam provides pipeline update on Fitusiran and Givosiran investigational RNAI therapeutic programs",
        "date": "09072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam provides pipeline update on Fitusiran and Givosiran investigational RNAI therapeutic programs "
    },
    {
        "content": "* Alnylam Pharmaceuticals reports second quarter 2017 financial results and highlights recent period activity",
        "date": "08092017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports Q2 adj loss per share $1.07 "
    },
    {
        "content": "* Alnylam and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study with investigational RNAI therapeutic Fitusiran in patients with hemophilia A and B with or without inhibitors",
        "date": "07102017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study "
    },
    {
        "content": "* Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran",
        "date": "07072017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran "
    },
    {
        "content": "* Alnylam reports new positive clinical results for Givosiran (ALN-AS1)  an investigational RNAI therapeutic for the treatment of acute hepatic porphyrias",
        "date": "06262017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports results for Givosiran "
    },
    {
        "content": "* Alnylam CEO  John Maraganore  named BIO chair for 2017-2018 term",
        "date": "06192017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam CEO  John Maraganore  named BIO chair for 2017-2018 term "
    },
    {
        "content": "* Alnylam significantly expands patent portfolio with new allowances from United States Patent and Trademark Office Source text for Eikon: Further company coverage:",
        "date": "06122017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam expands patent portfolio with allowances from U.S. Patent and Trademark Office "
    },
    {
        "content": "* Company updated its cash guidance for year ending december 31  2017 - sec filing",
        "date": "06062017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals expects to end 2017 with over $1 bln in cash  cash equivalents  fixed income marketable securities "
    },
    {
        "content": "* FDA grants Breakthrough Therapy Designation for Alnylam\u2019S Givosiran for the prophylaxis of attacks in patients with acute hepatic porphyria",
        "date": "05312017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-FDA grants Breakthrough Therapy Designation for Alnylam\u2019S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria "
    },
    {
        "content": "* Alnylam Pharmaceuticals announces proposed public offering of common stock",
        "date": "05232017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports proposed public offering of common stock "
    },
    {
        "content": "* Alnylam Pharmaceuticals prices public offering of common stock",
        "date": "05242017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals prices public offering of common stock "
    },
    {
        "content": "* Alnylam Pharmaceuticals Inc - appointment of Manmeet S. Soni as  chief financial officer Source text for Eikon: Further company coverage:",
        "date": "05092017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer "
    },
    {
        "content": "* Files for potential mixed shelf offering; size not disclosed Source text: (bit.ly/2pNQPaG) Further company coverage:",
        "date": "05052017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals files for potential mixed shelf offering "
    },
    {
        "content": "* Alnylam pharmaceuticals reports first quarter 2017 financial results and highlights recent period activity",
        "date": "05052017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports Q1 loss per share of $1.25 including items "
    },
    {
        "content": "* ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN  AN INVESTIGATIONAL RNAI THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS",
        "date": "04262017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN "
    },
    {
        "content": "* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran",
        "date": "04262017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Medicines Co  Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran "
    },
    {
        "content": "* Announced a program in partnership with Alnylam Pharmaceuticals to provide genetic testing for hereditary ATTR (HATTR) amyloidosis Source text for Eikon: Further company coverage:",
        "date": "04032017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Invitae Corp announces a program in partnership with Alnylam Pharmaceuticals "
    },
    {
        "content": "* Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran  an investigational rnai therapeutic for the treatment of acute hepatic porphyrias",
        "date": "03012017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran "
    },
    {
        "content": "* Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity",
        "date": "02082017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity "
    },
    {
        "content": "* ALNYLAM PHARMACEUTICALS INC - ANNOUNCED NEW RESULTS FROM AN EXPLORATORY ANALYSIS OF ITS PHASE 1 STUDY WITH FITUSIRAN",
        "date": "02022017",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-ALNYLAM PRESENTS NEW DATA ON FITUSIRAN AT EAHAD "
    },
    {
        "content": "* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)",
        "date": "11152016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-The Medicines Company  Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran "
    },
    {
        "content": "* Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders",
        "date": "11142016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision "
    },
    {
        "content": "* Results from study showed doses \u007f300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months",
        "date": "11132016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals  Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran "
    },
    {
        "content": "* Alnylam pharmaceuticals reports third quarter 2016 financial results and highlights recent period activity",
        "date": "11022016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports Q3 loss per share $1.21 including items "
    },
    {
        "content": "Alnylam Pharmaceuticals Inc said on Wednesday it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure  after a late-stage study showed that patients given the drug were more likely to die than patients treated with a placebo.",
        "date": "10052016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "Alnylam ends development of drug due to patient deaths in trial "
    },
    {
        "content": "* Data monitoring committee recommends continuation of Apollo phase 3 clinical trial of patisiran for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)",
        "date": "10102016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals -Data monitoring committee recommends continuation of Apollo phase 3 clinical trial of Patisiran "
    },
    {
        "content": "* Decision to discontinue development of revusiran does not affect patisiran",
        "date": "10052016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharma says discontinues revusiran development "
    },
    {
        "content": "* Presents clinical and non clinical data demonstrating continued rnai platform optimization and leadership in the development of rna-based therapeutics at 12th annual meeting of the Oligonucleotide Therapeutics Society",
        "date": "09282016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam presents clinical and non-clinical data "
    },
    {
        "content": "* Alnylam expands and strengthens management team as it plans for commercialization",
        "date": "09192016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam expands and strengthens management team as it plans for commercialization "
    },
    {
        "content": "* Alnylam completes enrollment in endeavour phase 3 study with revusiran  an investigational rnai therapeutic for patients with hereditary attr amyloidosis with cardiomyopathy (hattr-cm)",
        "date": "08082016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam completes enrollment in phase 3 study with revusiran "
    },
    {
        "content": "* Company updates guidance for phase 3  and now plans to start studies in early 2017",
        "date": "07252016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharma Announces New Positive Interim Phase 1 Study Results for Fitusiran "
    },
    {
        "content": "* Alnylam initiates phase 1/2 clinical trial for ALN-HBV  an investigational RNAI therapeutic for the treatment of chronic Hepatitis B virus infection",
        "date": "07072016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam initiates Phase 1/2 clinical trial for ALN-HBV "
    },
    {
        "content": "* Appointed David-Alexandre Gros  M.D. Senior VP and chief business officer to serve as principal financial officer",
        "date": "06152016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals names David-Alexandre Gros Principal Financial Officer "
    },
    {
        "content": "* Begins strategic collaboration with Alnylam to discover novel RNAi therapeutic products;financial terms of agreement were not disclosed",
        "date": "05242016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Bioxcel Corp says begins collaboration with Alnylam to discover novel RNAi therapeutic products "
    },
    {
        "content": "* Q1 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S",
        "date": "05022016",
        "name": "Alnylam Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "ALNY",
        "title": "BRIEF-Alnylam Pharmaceuticals reports Q1 GAAP loss per share $1.21 including items "
    }
]